Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194946 | 0.94 | MAPT (0.46) | ATMCYP2C19L3MBTL1KDM4EMAPT | |
| SCHEMBL5791367 | 0.84 | CYP2C9 (0.46) | CYP2C19CYP2C9ALDH1A1KDM4ELMNA | |
| SCHEMBL6570768 | 0.83 | KDM4E (0.44) | CYP2C19ALDH1A1NPC1CASP1RAB9A | |
| SCHEMBL8979701 | 0.82 | MKNK1 (0.37) | CYP11B1CYP11B2NPC1RAB9AKDM4E | |
| SCHEMBL9349704 | 0.80 | CYP2C9 (0.34) | ATMCYP2C19CYP2C9L3MBTL1MAPT | |
| SCHEMBL6570774 | 0.78 | PLA2G2A (0.41) | ALDH1A1NPC1CASP1RAB9AL3MBTL1 | |
| SCHEMBL5952565 | 0.77 | NPC1 (0.50) | ALDH1A1NPC1CASP1RAB9AL3MBTL1 | |
| SCHEMBL9199886 | 0.77 | KDM4E (0.46) | CYP2C19ALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL12502665 | 0.74 | CYP11B1 (0.35) | CYP2C9CYP11B1CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL56951 | 0.74 | ATM (0.77) | ATMCYP2C19CYP2A6CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | Georgetown University Office of Technology Commercialization (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2007115092-A2 | 10-SUBSTITUTED CYTISINE DERIVATIVES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-5502065-A | TREATING HEADACHES | PFIZER INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0636129-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1995-02-01 | — | — | EP | disclosed |
| CN-1082040-A | Indoles | PFIZER RES & DEV (IE) | 1994-02-16 | — | — | CN | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | CHRNA10, CHRNA5, CHRNA1 | ATM 3508/4885CYP2C19 664/4885CYP2A6 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.